Ketamine Research & Evidence
Clinical evidence, meta-analyses, mechanisms (BDNF, glutamate, neuroplasticity), biomarkers, and outcome data for low-dose ketamine.
Evidence first
Use this hub to understand study design, endpoints, and limitations before making treatment assumptions.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.
Featured
3 articles
Ketamine and Immune Function: Immunomodulatory Effects of Low-Dose Ketamine
A research-focused review of ketamine's effects on the immune system, including its impact on innate and adaptive immunity, inflammatory cytokines, immune cell function, and implications for patients with autoimmune conditions and chronic inflammation.
Ketamine and the Gut-Brain Axis: How the Microbiome Influences Treatment Response
An in-depth look at the emerging research connecting ketamine therapy to the gut-brain axis, including how gut microbiome composition may predict and modulate ketamine's antidepressant and analgesic effects.
Low-Dose Ketamine Case Studies: Clinical Outcomes and Lessons
Review five low-dose ketamine composite case studies, including depression, PTSD, CRPS, bipolar depression, and suicidal ideation, with research-backed clinical lessons.
Ketamine and Immune Function: Immunomodulatory Effects of Low-Dose Ketamine
A research-focused review of ketamine's effects on the immune system, including its impact on innate and adaptive immunity, inflammatory cytokines, immune cell function, and implications for patients with autoimmune conditions and chronic inflammation.
Ketamine and the Gut-Brain Axis: How the Microbiome Influences Treatment Response
An in-depth look at the emerging research connecting ketamine therapy to the gut-brain axis, including how gut microbiome composition may predict and modulate ketamine's antidepressant and analgesic effects.
Low-Dose Ketamine Case Studies: Clinical Outcomes and Lessons
Review five low-dose ketamine composite case studies, including depression, PTSD, CRPS, bipolar depression, and suicidal ideation, with research-backed clinical lessons.
How to Start a Ketamine Therapy Practice: A Clinician's Guide
A clinician guide to starting a ketamine therapy practice, covering registration, state review, protocols, monitoring, compounding, documentation, staffing, and referrals.
The Complete Guide to Low-Dose Ketamine Therapy
A comprehensive, evidence-based guide covering what low-dose ketamine is, how it works, all routes of administration, what patients can expect during treatment, efficacy data across conditions, safety considerations, and how to find qualified providers.
What Is the Response Rate for Ketamine Therapy?
Approximately 50 to 70 percent of patients with treatment-resistant depression respond to a course of low-dose ketamine infusions.
Ketamine and Neuroinflammation: How Anti-Inflammatory Effects Support Mental Health
Ketamine lowers inflammatory cytokines and calms microglia, effects that support its antidepressant action alongside biomarker and questionnaire monitoring.
Biomarkers for Predicting Ketamine Treatment Response
A review of emerging biological markers that may predict which patients will respond to ketamine therapy, including inflammatory markers, neuroimaging signatures, genetic polymorphisms, and electrophysiological features.
Sex Differences in Ketamine Treatment Response: Hormonal and Genetic Factors
What research says about sex differences in ketamine treatment response, including hormones, genetics, dosing questions, and the limits of current clinical evidence.
Glutamate System Modulation by Low-Dose Ketamine
Glutamate system modulation by low-dose ketamine works through NMDA receptor blockade, an AMPA-driven glutamate surge, and BDNF-linked plasticity.
Ketamine Effects on Sleep Architecture: Slow-Wave Sleep and REM Changes
How does low-dose ketamine affect sleep? Review of slow-wave sleep enhancement, REM modulation, and links between sleep architecture and antidepressant action.
Telehealth Ketamine Marketing Compliance: Regulatory and Ethical Guidelines
Learn how telehealth ketamine marketing can address off-label use, FTC health claims, DEA telemedicine rules, REMS distinctions, and state-specific review needs.
Anti-Inflammatory Properties of Low-Dose Ketamine: Cytokine Modulation
Low-dose ketamine lowers IL-6 and TNF-alpha via NF-kappaB inhibition. See how cytokine modulation shapes its antidepressant and pain effects.
BDNF Signaling and Ketamine's Antidepressant Action
A detailed examination of how ketamine activates brain-derived neurotrophic factor signaling, TrkB receptor pathways, and the mTOR cascade to produce rapid antidepressant effects. Covers molecular mechanisms, clinical evidence, and implications for personalized treatment.
Neuroplasticity Mechanisms in Ketamine Therapy
An in-depth exploration of how low-dose ketamine promotes neural rewiring, synaptogenesis, and dendritic spine formation. This article examines the molecular and cellular pathways through which ketamine restores synaptic connectivity in mood and pain disorders.
Ketamine-Opioid System Interactions: Naltrexone Studies and Debate
How ketamine interacts with opioid receptors, what the naltrexone blockade study found, and what it means for patients on opioid medications.
Ketamine and the Default Mode Network: Neuroimaging Evidence
How does ketamine affect the brain's default mode network? A review of fMRI, MEG, and PET studies on DMN connectivity, depression, and treatment response.
Low-Dose Ketamine for Acute Suicidal Ideation: Clinical Evidence
A review of the clinical trial evidence examining low-dose ketamine as an intervention for acute suicidal ideation. This article evaluates randomized controlled trials, naturalistic studies, and emergency department protocols demonstrating ketamine's rapid anti-suicidal effects.
Ketamine, Neuroplasticity, and Brain-Derived Neurotrophic Factor
How does low-dose ketamine drive neuroplasticity? A look at BDNF release, TrkB and mTOR activation, and the synapse rebuilding behind its rapid antidepressant effect.
Meta-Analyses of Low-Dose Ketamine for Treatment-Resistant Depression
Meta-analyses of low-dose ketamine for treatment-resistant depression show large 24-hour effects and better durability for racemic ketamine than esketamine.
Rapid-Onset Antidepressant Mechanisms of Low-Dose Ketamine
Low-dose ketamine's rapid-onset antidepressant mechanisms explain why relief begins in hours, not weeks, via NMDA blockade and BDNF-driven synaptic growth.